Literature DB >> 29020381

Antibody Banding Patterns of the Enzyme-Linked Immunoelectrotransfer Blot and Brain Imaging Findings in Patients With Neurocysticercosis.

Gianfranco Arroyo1,2,3, Silvia Rodriguez4, Andres G Lescano1,2,3, Karen A Alroy5, Javier A Bustos1,2,3,4, Saul Santivañez6, Isidro Gonzales4, Herbert Saavedra4, E Javier Pretell7, Armando E Gonzalez8, Robert H Gilman5, Victor C W Tsang9, Hector H Garcia1,2,3,4.   

Abstract

Background: The enzyme-linked immunoelectrotransfer blot (EITB) assay is the reference serological test for neurocysticercosis (NCC). A positive result on EITB does not always correlate with the presence of active infections in the central nervous system (CNS), and patients with a single viable brain cyst may be EITB negative. Nonetheless, EITB antibody banding patterns appears to be related with the expression of 3 protein families of Taenia solium, and in turn with the characteristics of NCC in the CNS (type, stage, and burden of viable cysts).
Methods: We evaluated EITB antibody banding patterns and brain imaging findings of 548 NCC cases. Similar banding patterns were grouped into homogeneous classes using latent class analysis. The association between classes and brain imaging findings was assessed.
Results: Four classes were identified. Class 1 (patients negative or only positive to the GP50 band, related to the protein family of the same name) was associated with nonviable or single viable parenchymal cysticerci; class 2 (patients positive to bands GP42-39 and GP24, related to the T24-42 protein family, with or without anti-GP50 antibodies) was associated with intraparenchymal viable and nonviable infections; classes 3 and 4 (positive to GP50, GP42-39, and GP24 but also responding to low molecular weight bands GP21, GP18, GP14, and GP13, related to the 8 kDa protein family) were associated with extraparenchymal and intraparenchymal multiple viable cysticerci. Conclusions: EITB antibody banding patterns correlate with brain imaging findings and complement imaging information for the diagnosis of NCC and for staging NCC patients.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  EITB; Peru; Taenia solium; epilepsy; neurocysticercosis

Mesh:

Substances:

Year:  2018        PMID: 29020381      PMCID: PMC5850523          DOI: 10.1093/cid/cix774

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  31 in total

1.  Characterization and cloning of GP50, a Taenia solium antigen diagnostic for cysticercosis.

Authors:  Kathy Hancock; Sowmya Pattabhi; Ryan M Greene; Melinda L Yushak; Fatima Williams; Azra Khan; Jeffrey W Priest; Min Z Levine; Victor C W Tsang
Journal:  Mol Biochem Parasitol       Date:  2004-01       Impact factor: 1.759

Review 2.  Neurocysticercosis: the enigmatic disease.

Authors:  Svetlana Agapejev
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2011-12-01

Review 3.  The tetraspanin superfamily: molecular facilitators.

Authors:  H T Maecker; S C Todd; S Levy
Journal:  FASEB J       Date:  1997-05       Impact factor: 5.191

4.  Neurocysticercosis: is serology useful in the absence of brain imaging?

Authors:  Hector H Garcia; Silvia Rodriguez; Robert H Gilman; Armando E Gonzalez; Victor C W Tsang
Journal:  Trop Med Int Health       Date:  2012-07-19       Impact factor: 2.622

5.  Molecular cloning and characterisation of Ts8B1, Ts8B2 and Ts8B3, three new members of the Taenia solium metacestode 8 kDa diagnostic antigen family.

Authors:  Elizabeth Ferrer; Pedro Bonay; Mildred Foster-Cuevas; Luis Miguel González; Iris Dávila; María Milagros Cortéz; Leslie J S Harrison; R Michael E Parkhouse; Teresa Gárate
Journal:  Mol Biochem Parasitol       Date:  2006-12-15       Impact factor: 1.759

Review 6.  Revised diagnostic criteria for neurocysticercosis.

Authors:  O H Del Brutto; T E Nash; A C White; V Rajshekhar; P P Wilkins; G Singh; C M Vasquez; P Salgado; R H Gilman; H H Garcia
Journal:  J Neurol Sci       Date:  2016-11-21       Impact factor: 3.181

7.  Magnitude of the disease burden from neurocysticercosis in a developing country.

Authors:  C Bern; H H Garcia; C Evans; A E Gonzalez; M Verastegui; V C Tsang; R H Gilman
Journal:  Clin Infect Dis       Date:  1999-11       Impact factor: 9.079

Review 8.  Imaging findings in neurocysticercosis.

Authors:  Héctor H García; Oscar H Del Brutto
Journal:  Acta Trop       Date:  2003-06       Impact factor: 3.112

Review 9.  Immunological and molecular diagnosis of cysticercosis.

Authors:  Silvia Rodriguez; Patricia Wilkins; Pierre Dorny
Journal:  Pathog Glob Health       Date:  2012-09       Impact factor: 2.894

10.  Characterization of the 8-kilodalton antigens of Taenia solium metacestodes and evaluation of their use in an enzyme-linked immunosorbent assay for serodiagnosis.

Authors:  Kathy Hancock; Azra Khan; Fatima B Williams; Melinda L Yushak; Sowmya Pattabhi; John Noh; Victor C W Tsang
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

View more
  11 in total

Review 1.  Laboratory Diagnosis of Neurocysticercosis (Taenia solium).

Authors:  Hector H Garcia; Seth E O'Neal; John Noh; Sukwan Handali
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

2.  Spontaneously Arrested Transmission of Cysticercosis in a Highly Endemic Village with a Very Low Migration Rate.

Authors:  Oscar H Del Brutto; Seth E O'Neal; Pierre Dorny; Héctor H García
Journal:  Am J Trop Med Hyg       Date:  2017-12-14       Impact factor: 2.345

3.  Improved Diagnosis of Viable Parenchymal Neurocysticercosis by Combining Antibody Banding Patterns on Enzyme-Linked Immunoelectrotransfer Blot (EITB) with Antigen Enzyme-Linked Immunosorbent Assay (ELISA).

Authors:  Gianfranco Arroyo; Javier A Bustos; Andres G Lescano; Isidro Gonzales; Herbert Saavedra; E Javier Pretell; Yesenia Castillo; Erika Perez; Pierre Dorny; Robert H Gilman; Seth E O'Neal; Armando E Gonzalez; Hector H Garcia
Journal:  J Clin Microbiol       Date:  2021-12-01       Impact factor: 11.677

Review 4.  Taenia solium Cysticercosis and Its Impact in Neurological Disease.

Authors:  Hector H Garcia; Armando E Gonzalez; Robert H Gilman
Journal:  Clin Microbiol Rev       Date:  2020-05-27       Impact factor: 26.132

Review 5.  Neurocysticercosis: Current Perspectives on Diagnosis and Management.

Authors:  Caitlin Butala; T M Brook; Ayodele O Majekodunmi; Susan Christina Welburn
Journal:  Front Vet Sci       Date:  2021-05-10

6.  Imaging correlates of serum enzyme-linked immunoelectrotransfer blot (EITB) positivity in patients with parenchymal neurocysticercosis: results from 521 patients.

Authors:  Prabhakaran Vasudevan; Ranjith K Moorthy; Grace Rebekah; Ellen Jackson; Betcy Evangeline Pamela; Subashini Thamizhmaran; Josephin Manoj; Anupriya Thanigachalam; Douglas Drevets; Hélène Carabin; Vedantam Rajshekhar
Journal:  Trans R Soc Trop Med Hyg       Date:  2022-02-01       Impact factor: 2.455

Review 7.  Neurocysticercosis. A frequent cause of seizures, epilepsy, and other neurological morbidity in most of the world.

Authors:  J Bustos; I Gonzales; H Saavedra; S Handali; H H Garcia
Journal:  J Neurol Sci       Date:  2021-06-17       Impact factor: 4.553

8.  Mortality in Parenchymal and Subarachnoid Neurocysticercosis.

Authors:  Jesus Abanto; Daniel Blanco; Herbert Saavedra; Isidro Gonzales; Diego Siu; E Javier Pretell; Javier A Bustos; Hector H Garcia
Journal:  Am J Trop Med Hyg       Date:  2021-07-07       Impact factor: 3.707

9.  Feasibility of a point-of-care test based on quantum dots with a mobile phone reader for detection of antibody responses.

Authors:  Chan Lee; John Noh; Seth E O'Neal; Armando E Gonzalez; Hector H Garcia; Sukwan Handali
Journal:  PLoS Negl Trop Dis       Date:  2019-10-07

Review 10.  Unique Characteristics of Epilepsy Development in Neurocysticercosis.

Authors:  Jesica A Herrick; Javier A Bustos; Philip Clapham; Hector H Garcia; Jeffrey A Loeb
Journal:  Am J Trop Med Hyg       Date:  2020-05-14       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.